NEW YORK (GenomeWeb News) – Response Genetics today announced it is joining Blue Shield of California's provider network, giving members of the health plan access to the Los Angeles-based molecular diagnostic firm's test portfolio.
The deal is Response Genetics' first contract with an affiliate of Blue Cross Blue Shield. Blue Shield of California has about 3 million members.
Among the products offered by Response Genetics are tests for colon, lung, gastric, and melanoma cancers, as well as tests for the detection of EGFR mutations, KRAS mutations, and others.
The firm said earlier this week that its first-quarter revenues rose 40 percent year over year.
In afternoon trading shares of the company's stock on the Nasdaq was up 10 percent at $1.48.